RxDoctor Payments Data

Jeannette Chassaignac, MD

Urology · Lafayette, LANPI 1467540344

Payments from drug & device makers

$1,768in general payments, 2019–2025

Across 86 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$528
  • Astellas Pharma US Inc$427
  • Kerecis Limited$172
  • AMAG Pharmaceuticals, Inc.$115
  • Pfizer$102
  • Coloplast$94
  • plus $330 from 11 others

What the payments were for

  • Food & beverage$1,72598%
  • Education$442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,768 in reported general payments places this provider in the 35th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$249,575
Medicare patients
685
Services billed
13,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron193$128,319
MyrbetriqMirabegron191$111,811
Estradiol188$11,531
NitrofurantoinNitrofurantoin Macrocrystal454$9,637
Oxybutynin Chloride ErOxybutynin Chloride263$6,545
Methenamine Hippurate95$5,151
Potassium Citrate ErPotassium Citrate37$3,767
Tamsulosin Hcl198$2,370
Cefdinir147$1,733
Solifenacin Succinate59$1,478
YuvafemEstradiol14$881
Trimethoprim23$764
Finasteride61$627
Cephalexin37$394
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$19$128,319193 claims
Astellas Pharma US IncMyrbetriq$427$111,811191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 199 urology providers in Louisiana.

Other urology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →